Steven G DuBois
Dana-Farber Cancer Institute · Children's Oncology Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Steven G DuBois as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:12 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT03936465 · Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric CancerDana-Farber Cancer Institute · completed · Solid Tumor, Childhood, Lymphoma, Brain Tumor, Pediatric · principal investigator
- Ph3NCT03126916 · Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)Children's Oncology Group · recruiting · Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma · principal investigator
- Ph3NCT02306161 · Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing SarcomaNational Cancer Institute (NCI) · active not recruiting · Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:12 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Tumor and host markers of clinical outcomes after MIBG therapy in neuroblastomaR01CA214912 · NCI · DANA-FARBER CANCER INST · fiscal years 2018 to 2023 · $347,922 awarded in 2023Same name and institution; not confirmed by an ID
- Optimizing 131I-mIBG Therapy for Children with Advanced NeuroblastomaR01CA172067 · NCI · DANA-FARBER CANCER INST · fiscal years 2013 to 2017 · $363,425 awarded in 2017Same name and institution; not confirmed by an ID
- PhI trial of dual PI3K/BRD4 inhibitor SF1126 in neuroblastoma IND124993 (12/2/14)R01FD005740 · FDA · DANA-FARBER CANCER INST · fiscal years 2017 · $250,000 awarded in 2017Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- COG NCTN Network Group Operations CenterU10CA180886 · NCI · COG RESEARCH FOUNDATION, LLC · PI Douglas S. Hawkins · fiscal years 2014 to 2026Named on NCT03126916, NCT02306161
- Children's Oncology Group Chair's GrantU10CA098543 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI PETER C. ADAMSON · fiscal years 2003 to 2013Named on NCT02306161
Most cited trial papers
Clinical-trial papers with this author name in ewing sarcoma, ranked by citations from NIH iCite, fetched 2026-11-12 12:12 UTC. The ranking covers the 200 most relevant of 15 PubMed records, and a shared surname and initials can bring in a namesake. All 15 on PubMed
- Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group.Pediatr Blood Cancer · 201596 citationsRCR 3.0
- Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report.J Clin Oncol · 202191 citationsRCR 5.4
- 81 citationsRCR 7.8
- Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group.Pediatr Blood Cancer · 200953 citationsRCR 1.2
- Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma.Cancer Med · 202336 citationsRCR 3.3
- Long-Term Outcomes in Patients With Localized Ewing Sarcoma Treated With Interval-Compressed Chemotherapy on Children's Oncology Group Study AEWS0031.J Clin Oncol · 202326 citationsRCR 2.7
- Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group.Pediatr Blood Cancer · 202122 citationsRCR 1.2
- Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours.Eur J Cancer · 201621 citationsRCR 0.7
- Evaluation of polymorphisms in EWSR1 and risk of Ewing sarcoma: a report from the Childhood Cancer Survivor Study.Pediatr Blood Cancer · 20127 citationsRCR 0.2
- Patterns of Translocation Testing in Patients Enrolling in a Cooperative Group Trial for Newly Diagnosed Metastatic Ewing Sarcoma.Arch Pathol Lab Med · 20216 citationsRCR 0.3